Blockchain Registration Transaction Record

Quantum BioPharma Signs Agreement for Lucid-MS IND Application

Quantum BioPharma signs agreement with contract research organization to prepare Lucid-21-302 IND application targeting multiple sclerosis. The patented neuroprotective therapy aims to prevent demyelination, offering potential benefits for patients with MS and other neurodegenerative disorders.

This news is significant as it highlights Quantum BioPharma's progress in developing a novel therapy for multiple sclerosis, addressing a critical need for neuroprotective treatments. The agreement with a contract research organization marks a crucial step towards initiating a Phase 2 clinical trial, potentially offering new hope for patients with MS and other related disorders.